To: benzene-srp@listserve.api.org <benzene-srp@listserve.api.org>; benzene-erp@listserve.api.org <benzene-erp@listserve.api.org>
From: Bruce Jarnot <jarnotb@api.org>
Cc: Russell White <whiter@api.org>; Bruce Jarnot <jarnotb@api.org>
Bcc:
Received Date: 2007-07-30 15:03:37 GMT
Subject: Shanghai SRP, ERP... CC & DP/ME Mid-yr Progress Reports & Cover Memo

---

Dear SRP and ERP Members,

July 2007 progress reports for the Shanghai Health Study from Drs Irons and Wong are attached. These will be among the action items we will discuss during our August conference call that Bruce Jarnot is now organizing to replace the proposed research meeting in Boston, which too many of the Panel members could not attend due to scheduling conflicts.

I would draw your attention especially to the following sections of the two reports:

Richard Irons reports (p.3) that he intends to cease both follow-up activities for the Disease Progression study and routine hematology services (which I infer means diagnostic support to the Shanghai hospitals) by the end of July. Since the earliest cases of benzene poisoning, aplastic anemia and MDS that he could have enrolled in the DP study presented only 4 years ago, I have asked him if in fact there has been a long enough follow-up interval to make the disease progression study meaningful. Also, if the JCML is to cease diagnostic support for the Shanghai hospitals, which was originally intended to continue indefinitely, considerably more discussion is needed than a simple statement that this activity is now finished. I await his responses and will share them with you.

Otto Wong notes (p. 2 of his report) that some of the major participating hospitals seem not to have contributed any cases to the SHS for a considerable time. This raises a further concern about the completeness of case ascertainment for his case-control study, since for his study to be meaningful it has to rely on total or near-total case identification for both AML and lymphoid neoplasms presenting at all of the Shanghai hospitals during a defined period of time. The persistently low rate of participation in the lymphoid tumor arm of his study (39% at the Tumor Hospital during the first half of 2007) is a further complication. We will need to discuss this with both him and Richard Irons during the next series of conference calls.

I look forward to discussing these and related matters with you in the coming weeks.

With best regards,

Jerry Rice, Chair, SRP

Attachments:

CC Progress Report Jul-2007.pdf
DP ME Progress Report Jul-2007rev.pdf